Skip to main content

Drug Interactions between ethinyl estradiol / ethynodiol and relugolix

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ethinyl estradiol relugolix

Applies to: ethinyl estradiol / ethynodiol and relugolix

GENERALLY AVOID: Coadministration of hormonal contraceptives may decrease the efficacy of the fixed-dose oral formulation of relugolix, estradiol, and norethindrone when used for the management of uterine fibroids in premenopausal women. The effect of progestin-only contraceptives is unknown. Relugolix is an orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of relugolix results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased levels of the ovarian sex hormones estradiol and progesterone, and reduction of heavy menstrual bleeding in women with uterine fibroids. It has been suggested that uterine fibroid growth may be stimulated by estrogen and progesterone via paracrine mechanisms. However, combination with estradiol and norethindrone at doses lower than those used in combined hormonal contraceptives have been demonstrated in clinical studies to reduce hypoestrogenic effects and preserves bone mineral density. In addition, concomitant use of estrogen-containing hormonal contraceptives may lead to an increased risk of estrogen-related adverse effects such as breast tenderness/breast pain, abdominal pain, headache, edema, and arterial or venous thromboembolism.

MANAGEMENT: It is recommended that hormonal contraceptives (particularly those containing estrogen) should be discontinued prior to starting treatment with the fixed-dose oral formulation containing relugolix, estradiol, and norethindrone (brand name Myfembree). Some authorities consider their concomitant use to be contraindicated (UK). The manufacturer of Myfembree recommends using effective non-hormonal contraception during treatment and for one week after the final dose. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2021) "Product Information. Orgovyx (relugolix)." Myovant Sciences, Inc.
  3. (2023) "Product Information. Myfembree (estradiol/norethindrone/relugolix)." Myovant Sciences, Inc.
  4. Hsin-Yuan C, Mohamed A, Yi-Fen C, et al. (2022) An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2030705
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Minor

ethinyl estradiol food

Applies to: ethinyl estradiol / ethynodiol

Coadministration with grapefruit juice may increase the bioavailability of oral estrogens. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits. In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%. Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol. However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability. Also, the effect on other estrogens has not been studied.

References

  1. Weber A, Jager R, Borner A, et al. (1996) "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception, 53, p. 41-7
  2. Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T (1995) "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet, 20, p. 219-24

Switch to consumer interaction data

Minor

ethinyl estradiol food

Applies to: ethinyl estradiol / ethynodiol

The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory. The mechanism may be due to enzyme inhibition. Consider counseling women about this interaction which is unpredictable.

References

  1. Hobbes J, Boutagy J, Shenfield GM (1985) "Interactions between ethanol and oral contraceptive steroids." Clin Pharmacol Ther, 38, p. 371-80

Switch to consumer interaction data

Minor

ethynodiol food

Applies to: ethinyl estradiol / ethynodiol

The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory. The mechanism may be due to enzyme inhibition. Consider counseling women about this interaction which is unpredictable.

References

  1. Hobbes J, Boutagy J, Shenfield GM (1985) "Interactions between ethanol and oral contraceptive steroids." Clin Pharmacol Ther, 38, p. 371-80

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.